The European Medicines Agency has started a 'rolling review' of the COVID-19 vaccine being developed by Sanofi and GSK. The regulator said the review will be based on preliminary results from laboratory studies as well as early adult clinical studies that showed Vidprevtyn triggers antibodies against the virus.
Latest Video
New Stories
-
New research shows adult vaccination programs deliver major return on investment
April 26, 2024 - - Latest News -
Productivity Commission research backs the benefit of faster access to medicines
April 26, 2024 - - Latest News -
Let's make decisions based on credible information and not guesswork
April 24, 2024 - - Latest News -
Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate
April 24, 2024 - - Latest News -
Novartis nominates ex-BMS chief executive as its new chair
April 24, 2024 - - Latest News -
'The Pharmac system again, over about 33 years old, hasn’t really changed and evolved'
April 24, 2024 - - Latest News -
AusBiotech appoints experienced Sanofi leader as its new chief executive
April 23, 2024 - - Latest News